HSIC stock sentiment todayHenry Schein, Inc.
Sentiment verdict
Gossip first, financials second — NEUTRAL at 72% confidence.
Last updated · cached analysis, refreshes periodically
HSIC
Henry Schein, Inc.Henry Schein remains a reliable dental market leader recovering from cyber-attack disruptions, but lacks the high-growth catalysts required for a 'Hot' rating.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for HSIC. Not financial advice.
Price · last 12 months
Gossip
Recent narrative has focused on the company's recovery from a significant late-2023 cyber-attack that hampered operations. Sentiment is currently transitioning from 'recovery mode' to 'efficiency mode' as the company targets margin expansion and cost-cutting initiatives.
- ·Cybersecurity recovery and business continuity
- ·Strategic BOLD program for cost savings
- ·Dental procedure volume stabilization
- ·Expansion into high-margin specialty products
Financial
Solid balance sheet with consistent free cash flow, though revenue growth is currently modest (low single digits). Valuation is reasonable at a forward P/E of roughly 16x, slightly below historical averages.
- ·Forward P/E: ~16.5x
- ·Operating Margin: ~7-8%
- ·Return on Invested Capital (ROIC): ~10%
- ·Debt-to-Equity: ~0.55
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $692K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Exposure to discretionary consumer spending for dental implants
- ·Ongoing threat of cyber-attacks in medical distribution
- ·Consolidation of dental service organizations (DSOs) pressuring margins
Peer temperature
How direct competitors stack up against HSIC right now.
- COLDPDCOPatterson Companies
COLDER — higher exposure to volatile animal health markets and weaker operating margins compared to HSIC.
See full analysis → - NEUTRALXRAYDentsply Sirona
NEUTRAL — trading at a similar valuation but facing more intense regulatory and internal restructuring headwinds.
See full analysis → - HOTENVEnvista Holdings
HOTTER — high-risk/reward play trading at a deeper discount with significant upside if recent management changes spark a turnaround.
See full analysis →
- HSIC+0.2%
- PDCO—
- XRAY-17.4%
- ENV—
Analyst price target
Consensus average of 14 analysts · median 100.00
Source: StockAnalysis.com · updated 2026-08-19
AI-generated analysis for informational purposes only. Not financial advice.